We thus hypothesized that different TP53 mutations in SCLC classified as disruptive (hemizygous deletion; truncation) or non-disruptive (in-frame; missense; GOF) mutations may be useful as predictive biomarkers for PLK1 inhibitor therapy. This evidence concerns the gene TP53 and small cell lung carcinoma.